ArticleClinical and experimental immunology1995
The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the rat.
Article in Clinical and experimental immunology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 35 citations in OpenAlex.
- Drug Delivery System Approaches for Rheumatoid Arthritis Treatment: A Review.Mini reviews in medicinal chemistry · 2024Review
- Zoledronate alters natural progression of tissue-engineered vascular grafts.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells.Oncology reports · 2019Article
- Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling.Cell reports · 2018Article
- The Role of Microparticles in Rheumatic Diseases and their Potentials as Therapeutic Tools.Journal of molecular immunology · 2016Article
- Nanoparticle clearance is governed by Th1/Th2 immunity and strain background.The Journal of clinical investigation · 2013Article
- Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.Journal of the Royal Society, Interface · 2010Review
- Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis.Annals of the rheumatic diseases · 2004Article
- Drugs in development: bisphosphonates and metalloproteinase inhibitors.Arthritis research & therapy · 2003Review
- Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant-induced arthritis.Clinical and experimental immunology · 1995Article
- Methods for assessing splenic macrophage depletion by liposome encapsulated clodronate.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clodronate, encapsulated within small unilamellar vesicles (SUVc) will deplete hepatic macrophages after intravenous injection. Functional studies, using probes to evaluate hepatic Fc and C3b uptake, showed a close correlation between the inhibition of receptor-mediated uptake and the depletion of hepatic macrophages. Twenty milligrams of clodronate encapsulated within SUVc produced > or = 90% inhibition of uptake and clearance of Fc- and C3b-coated erythrocytes and a comparable reduction of hepatic macrophage numbers. Inhibition of macrophage receptor-mediated uptake of these erythrocytes was closely related to the reduction in macrophage numbers. Repopulation of macrophages within the liver took place over 2 weeks. At 1 week after depletion, although repopulation was taking place, receptor-mediated function remained suppressed. In a preliminary experiment, treatment of rats with adjuvant arthritis with 20 mg clodronate encapsulated in SUV suppressed the inflammation and reversed the course of the disease, while treatment with 20 mg free clodronate in saline or 20 mg clodronate in multilamellar vesicles (MLVc) did not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.